Latest News and Press Releases
Want to stay updated on the latest news?
-
Development milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus’ pivotal FELIX Phase 2 trial, announced in a separate press release...
-
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
-
– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country – Durability and favorable toxicity profile of...